My writing focuses on peptide science, metabolic medicines, and the practical reading of clinical research. My topics include receptor biology, oral delivery, pharmaceutical quality, and the difference between an interesting mechanism and an established clinical outcome.
My LinkedIn profile lists a Doctor of Pharmacy (PharmD) qualification and work spanning peptide therapeutics, metabolic health, and pharmacy. In this publication, I emphasize original studies and current regulatory information.
Oral semaglutide shows how a carefully studied formulation can overcome a delivery barrier—and why that evidence cannot be borrowed by every peptide capsule.
A receptor count cannot rank a medicine. Current US labels and the SURMOUNT-5 trial show why product, population and outcome must stay attached to every comparison.
Laboratory findings, a knee-pain series and a two-person safety pilot answer different questions. Follow the evidence before turning a plausible mechanism into a recovery claim.
A trial number begins an investigation. Use real BPC-157 and SELECT records to separate registration, results, absolute benefits, observed harms and a specific FDA approval.
A purity percentage answers a defined analytical question. Identity, amount, sterility, endotoxins, clinical benefit and regulatory approval each require their own evidence.
Peptide describes molecular construction. Sequence, targets, formulation and human evidence determine what a particular peptide can actually claim to do.
